US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain - Reuters
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S. Federal Trade Commission said on Tuesday.